Patents Assigned to Statens Serum Institut
-
Patent number: 7678544Abstract: The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum.Type: GrantFiled: May 18, 2005Date of Patent: March 16, 2010Assignees: Statens Serum Institut, Kobenhavns Universitet, Harold Wood HospitalInventors: Ulla M. Wewer, Bent Nørgaard-Pedersen, Michael Christiansen, Jennie Laigaard, Camilla Fröhlich, Kevin Spencer
-
Publication number: 20090186048Abstract: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.Type: ApplicationFiled: June 20, 2006Publication date: July 23, 2009Applicant: Statens Serum InstitutInventors: Claus Aagaard, Carina Vingsbo-Lundberg, Peter Andersen
-
Publication number: 20080299151Abstract: Described herein are vaccines and the use of naked DNA and/or RNA encoding hemagglutinin (HA) from pandemic influenza, e.g., the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus, as a vaccine component against present day and coming H1, H2, H3, H5, N1, N2 containing influenza A infections in humans and swine optionally with the naked DNA and/or RNA encoding Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from pandemic influenza virus included. If the vaccine components are used as DNA or RNA vaccines with or without the corresponding protein, the codons can optionally be “humanized” using preferred codons from highly expressed mammalian genes and the administration of this DNA vaccine can be by saline or buffered saline injection of naked DNA or RNA, or injection of DNA plasmid or linear gene expressing DNA fragments coupled to particles. Addition of the matrix protein (M) and/or the nucleoprotein (NP) from the 1918 influenza strain is also disclosed.Type: ApplicationFiled: May 30, 2008Publication date: December 4, 2008Applicant: Statens Serum InstitutInventor: Anders Fomsgaard
-
Publication number: 20080267990Abstract: The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as diagnostic reagents containing the polypeptides.Type: ApplicationFiled: November 1, 2007Publication date: October 30, 2008Applicant: STATENS SERUM INSTITUTInventors: Peter Andersen, Karin Weldingh, Christina Veggerby Hansen, Walter Florio, Li Mei Meng Okkels, Rikke Louise Vinther Skjot, Peter Birk Rasmussen
-
Publication number: 20080090761Abstract: The present nanofiltration method is applicable on solutions of plasma-derived and recombinantly produced MBL. The MBL containing solution is subjected to a pre-treatment prior to the nanofiltration step. The nanofiltration is used for removal of viruses in general and other infectious agents to obtain an MBL product free from infectious viruses and agents. The nanofiltered MBL product is ready for preparing a pharmaceutical composition for therapeutic or prophylactic treatment of infections and other diseases in individuals with MBL deficiency and insufficiency.Type: ApplicationFiled: September 30, 2005Publication date: April 17, 2008Applicant: STATENS SERUM INSTITUTInventor: Inga Laursen
-
Publication number: 20070184073Abstract: The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as diagnostic reagents containing the polypeptides.Type: ApplicationFiled: August 2, 2005Publication date: August 9, 2007Applicant: STATENS SERUM INSTITUTInventors: Peter Andersen, Karin Weldingh, Christina Hansen, Walter Florio, Li Mei Okkels, Rikke Skjot, Peter Rasmussen
-
Patent number: 7138120Abstract: The present invention relates to a process for purifying immunoglobulin G from a crude immunoglobulin-containing plasma protein fraction. Said process includes a number of steps of which the anion exchange chromatography and the cation exchange chromatography are preferably connected in series. An acetate buffer having a pH of about 5.0-6.0 and having a molarity of about 5-25 mM is preferably used throughout the purification process. The invention further comprises an immunoglobulin product which is obtainable by this process. The invention also relates to an immunoglobulin product which has a purity of more than 98%, has a content of IgG monomers and dimers of more than 98.5%, has a content of IgA less than 4 mg of IgA/l, and contains less than 0.5% polymers and aggregates. Said product does not comprise detergent, PEG or albumin as a stabilizer. The product is stable, virus-safe, liquid and ready for instant intravenous administration.Type: GrantFiled: July 10, 2001Date of Patent: November 21, 2006Assignee: Statens Serum InstitutInventors: Inga Laursen, Børge Teisner
-
Patent number: 7037510Abstract: The present invention discloses fusion proteins of the immunodominant antigens ESAT-6 and Ag85B from Mycobacterium tuberculosis or homologues thereof, and a tuberculosis vaccine based on the fusion proteins, which vaccine induces efficient immunological memory.Type: GrantFiled: March 13, 2001Date of Patent: May 2, 2006Assignee: Statens Serum InstitutInventors: Peter Andersen, Anja Weinreich Olsen, Rikke Louise Vinther Skjøt, Peter Birk Rasmussen
-
Patent number: 6991797Abstract: The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides.Type: GrantFiled: March 13, 2001Date of Patent: January 31, 2006Assignee: Statens Serum InstitutInventors: Peter Andersen, Rikke Louise Vinther Skjøt
-
Publication number: 20060008519Abstract: The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.Type: ApplicationFiled: July 5, 2005Publication date: January 12, 2006Applicant: Statens Serum InstitutInventors: Jesper Davidsen, Peter Andersen, Ida Rosenkrands
-
Patent number: 6982085Abstract: The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as diagnostic reagents containing the polypeptides.Type: GrantFiled: May 2, 2002Date of Patent: January 3, 2006Assignee: Statens Serum InstitutInventors: Peter Andersen, Karin Weldingh, Christina Veggerby Hansen, Walter Florio, Li Mei Meng Okkels, Rikke Louise Vinther Skjot, Peter Birk Rasmussen
-
Publication number: 20050191308Abstract: An adjuvant combination and a kit useful for immunization is provided. The kit contains an antigenic substance and an adjuvant combination of dimethyl dioctadecyl ammonium bromide (DDA-Br or DDA-Cl) with a monophosphoryl lipid.Type: ApplicationFiled: September 3, 2003Publication date: September 1, 2005Applicant: Statens Serum InstitutInventors: Erik Lindblad, Martin Elhay, Peter Andersen, Lise Brandt
-
Patent number: 6921808Abstract: A purification process for large-scale production of Gc-globulin is described. The source of Gc-globulin is preferably a crude plasma fraction but can be any solution, suspension or supernatant containing Gc-globulin, e.g., a milk product, colostrum or a fermentation broth. The Gc-globulin can be plasma-derived or produced by a genetic modified organism. The process includes two key elements: purification by series of ion exchange chromatography steps, and performing at least two virus-reduction steps. A diagnostic method to measure the free Gc-globulin in a patient blood sample, a use of Gc-globulin in medicine and the preparation of a Gc-globulin medicinal product is also provided. The product can be used in therapy for patients with circulatory disorders and complications, i.e., where it is contemplated that patients would benefit from the administration of Gc-globulin.Type: GrantFiled: August 18, 2004Date of Patent: July 26, 2005Assignee: Statens Serum InstitutInventors: Charlotte Svaerke Joergensen, Inga Laursen, Gunnar Houen
-
Publication number: 20050020816Abstract: A purification process for large-scale production of Gc-globulin is described. The source of Gc-globulin is preferably a crude plasma fraction but can be any solution, suspension or supernatant containing Gc-globulin, e.g., a milk product, colostrum or a fermentation broth. The Gc-globulin can be plasma-derived or produced by a genetic modified organism. The process includes two key elements: purification by series of ion exchange chromatography steps, and performing at least two virus-reduction steps. A diagnostic method to measure the free Gc-globulin in a patient blood sample, a use of Gc-globulin in medicine and the preparation of a Gc-globulin medicinal product is also provided. The product can be used in therapy for patients with circulatory disorders and complications, i.e., where it is contemplated that patients would benefit from the administration of Gc-globulin.Type: ApplicationFiled: August 18, 2004Publication date: January 27, 2005Applicant: Statens Serum InstitutInventors: Charlotte Joergensen, Inga Laursen, Gunnar Houen
-
Patent number: 6806355Abstract: A purification process for large-scale production of Gc-globulin is described. The source of Gc-globulin is preferably a crude plasma fraction but can be any solution, suspension or supernatant containing Gc-globulin, e.g. a milk product, colostrum or a fermentation broth. The Gc-globulin can be plasma-derived or produced by a genetic modified organism. The process includes two key elements: purification by series of ion exchange chromatography steps, and performing at least two virus-reduction steps. A diagnostic method to measure the free Gc-globulin in a patient blood sample, a use of Gc-globulin in medicine and the preparation of a Gc-globulin medicinal product is also provided. The product can be used in therapy for patients with circulatory disorders and complications, i.e. where it is contemplated that patients would benefit from the administration of Gc-globulin.Type: GrantFiled: August 13, 2002Date of Patent: October 19, 2004Assignee: Statens Serum InstitutInventors: Charlotte Svaerke Joergensen, Inga Laursen, Gunnar Houen
-
Publication number: 20040086949Abstract: The present invention relates to a method for preparing a ligand presenting assembly (LPA), an LPA, an immunological composition and a vaccine. The invention further relates to a method for generating antibodies, a kit for use in diagnosis and use of an LPA for preparing a pharmaceutical composition.Type: ApplicationFiled: December 1, 2003Publication date: May 6, 2004Applicant: Statens Serum InstitutInventors: Arne Holm, Rikke Malene Jorgensen, Soren Ostergaard, Michael Theisen
-
Patent number: 6649409Abstract: The present invention relates to a method for producing a nucleotide sequence construct with optimized codons for an HIV genetic vaccine based on a primary, early HIV isolate. Specific such nucleotide sequence construct are the synthetic envelope BX08 constructs. The invention further relates to the medical use of such constructs for the treatment and prophylaxis of HIV through DNA vaccine and for diagnostics.Type: GrantFiled: March 29, 2000Date of Patent: November 18, 2003Assignee: Statens Serum InstitutInventor: Anders Fomsgaard
-
Patent number: 6649170Abstract: A kit useful for immunization is described. The kit contains an antigenic substance from a Mycobacterium and an adjuvant combination of dimethyl dioctadecyl ammonium bromide and monophosphoryl lipid A.Type: GrantFiled: May 12, 1999Date of Patent: November 18, 2003Assignee: Statens Serum InstitutInventors: Erik B. Lindblad, Martin J. Elhay, Peter Andersen, Lise Ostergaard Brandt
-
Patent number: 6641814Abstract: The present invention is based on the identification and characterization of a number of M. tuberculosis derived novel proteins and protein fragments (SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 17-23, 42, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72-86, 88, 90, 92, 94, 141, 143, 145, 147, 149, 151, 153, and 168-171). The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides. Another part of the invention is based on the surprising discovery that fusions between ESAT-6 and MPT59 are superior immunogens compared to each of the unfused proteins, respectively.Type: GrantFiled: March 30, 1998Date of Patent: November 4, 2003Assignee: Statens Serum InstitutInventors: Peter Andersen, Rikke Nielsen, Thomas Oettinger, Peter Birk Rasmussen, Ida Rosenkrands, Karin Weldingh, Walter Florio
-
Publication number: 20030138866Abstract: A diagnostic method is disclosed which utilizes short C-terminal fragments of Borrelia burgdorferi sensu lato derived protein OspC. The 4 amino-terminal acids Pro-Lys-Pro (SEQ ID NO: 22) are shown to be essential in immune reactivity between sera from patients suffering from early borreliosis and various OspC derivatives and it is shown that in order to be effective as a diagnostic agent, 5 consecutive amino acid residues long homologue of a fragment identical to the 10 C-terminal amino acids of OspC (SEQ DI NO: 1). Also disclosed are vaccines utilizing the short peptides as well as methods for their preparation.Type: ApplicationFiled: October 10, 2001Publication date: July 24, 2003Applicant: Statens Serum InstitutInventors: Marianne Jartved Mathiesen, Michael Theisen, Arne Holm, Soren Ostergaard